(Q34036687)

30 July 2017

title

Controversies in primary treatment of low-risk papillary thyroid cancer (English)

1 reference

30 July 2017

1 reference

Donald S A McLeod

1

1 reference

30 July 2017

Anna M Sawka

series ordinal

2

1 reference

30 July 2017

David S Cooper

series ordinal

3

1 reference

30 July 2017

language of work or name

English

0 references

publication date

22 March 2013

1 reference

30 July 2017

1 reference

30 July 2017

volume

381

1 reference

30 July 2017

issue

9871

1 reference

30 July 2017

page(s)

1046-1057

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

30 July 2017

1 reference

7 January 2021

Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I : practice recommendations of the American Thyroid Association.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Progress in molecular-based management of differentiated thyroid cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Increasing incidence of thyroid cancer in the United States, 1973-2002

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Increasing detection and increasing incidence in thyroid cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Increasing incidence of thyroid cancer is due to increased pathologic detection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

The increasing incidence of small thyroid cancers: where are the cases coming from?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Increasing thyroid cancer incidence in Canada, 1970-1996: time trends and age-period-cohort effects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Unexpected additional increase in the incidence of thyroid cancer among a recent birth cohort in Switzerland

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

A time trend analysis of papillary and follicular cancers as a function of tumour size: a study of data from six cancer registries in France (1983-2000).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Incidence of thyroid cancer in Italy, 1991-2005: time trends and age-period-cohort effects.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Thyroid cancer in Denmark 1943-2008, before and after iodine supplementation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Thyroid cancer incidence among active duty U.S. military personnel, 1990-2004

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Improved detection does not fully explain the rising incidence of well-differentiated thyroid cancer: a population-based analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Descriptive epidemiology of thyroid carcinoma in Carinthia, Austria: 1984-2001. Histopathologic features and tumor classification of 734 cases under elevated general iodination of table salt since 1990: population-based age-stratified analysis on th

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Aggressive variants of papillary thyroid cancer: incidence, characteristics and predictors of survival among 43,738 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Staging systems for papillary thyroid carcinoma: a study of 2 tertiary referral centers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Current trends in TSH suppression therapy for patients with papillary thyroid carcinoma in Japan: results of a questionnaire distributed to councilors of the Japanese Society of Thyroid Surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Associat

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Is total thyroidectomy the best possible surgical management for well-differentiated thyroid cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Optimal surgery for papillary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Multiple thyroid involvement (intraglandular metastasis) in papillary thyroid carcinoma. A clinicopathologic study of 105 consecutive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Hayes Martin Lecture. Our AMES is true: how an old concept still hits the mark: or, risk group assignment points the arrow to rational therapy selection in differentiated thyroid cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Treatment of thyroid cancer based on risk groups.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

The importance of surgeon experience for clinical and economic outcomes from thyroidectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Low-risk differentiated thyroid cancer: the need for selective treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Selective surgery and adjuvant therapy based on risk classifications of well-differentiated thyroid cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Natural history, treatment, and course of papillary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Recurrence after treatment of micropapillary thyroid cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Extent of surgery affects survival for papillary thyroid cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Extent of thyroidectomy is not a major determinant of survival in low- or high-risk papillary thyroid cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Surgery for papillary thyroid carcinoma: is lobectomy enough?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Optimal treatment strategy in patients with papillary thyroid cancer: A decision analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Total thyroidectomy or thyroid lobectomy in patients with low-risk differentiated thyroid cancer: surgical decision analysis of a controversy using a mathematical model

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Cost-effective management of low-risk papillary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Consensus statement on the terminology and classification of central neck dissection for thyroid cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Modified neck dissection in treatment of thyroid cancer: a safe procedure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Macroscopic lymph-node involvement and neck dissection predict lymph-node recurrence in papillary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Significance of prophylactic modified radical neck dissection for patients with low-risk papillary thyroid carcinoma measuring 1.1-3.0 cm: first report of a trial at Kuma Hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

In papillary thyroid cancer, preoperative central neck ultrasound detects only macroscopic surgical disease, but negative findings predict excellent long-term regional control and survival

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Systematic review and meta-analysis of the adverse effects of thyroidectomy combined with central neck dissection as compared with thyroidectomy alone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Routine central neck dissection in differentiated thyroid carcinoma: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

American Thyroid Association design and feasibility of a prospective randomized controlled trial of prophylactic central lymph node dissection for papillary thyroid carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

The pros and cons of prophylactic central compartment lymph node dissection for papillary thyroid carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Prophylactic central neck dissection and local recurrence in papillary thyroid cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Outcome predictors and impact of central node dissection and radiometabolic treatments in papillary thyroid cancers < or =2 cm

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

A multicenter cohort study of total thyroidectomy and routine central lymph node dissection for cN0 papillary thyroid cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Optimization of staging of the neck with prophylactic central and lateral neck dissection for papillary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Influence of prophylactic central lymph node dissection on postoperative thyroglobulin levels and radioiodine treatment in papillary thyroid cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Complications of central neck dissection in patients with papillary thyroid carcinoma: results of a study on 1087 patients and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Natural history and clinical outcome of differentiated thyroid carcinoma: a retrospective analysis of 1503 patients treated at a single institution

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Outcomes of patients with differentiated thyroid carcinoma following initial therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Use of radioactive iodine for thyroid cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Strategies of radioiodine ablation in patients with low-risk thyroid cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

To stimulate or withdraw? A cost-utility analysis of recombinant human thyrotropin versus thyroxine withdrawal for radioiodine ablation in patients with low-risk differentiated thyroid cancer in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Sialoadenitis secondary to ¹³¹I therapy for well-differentiated thyroid cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Nasolacrimal obstruction secondary to I(131) therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Second primary malignancies in thyroid cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Randomized Controlled Trial of a Computerized Decision Aid on Adjuvant Radioactive Iodine Treatment for Patients With Early-Stage Papillary Thyroid Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Iodine or Not (IoN) for low-risk differentiated thyroid cancer: the next UK National Cancer Research Network randomised trial following HiLo

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Thyrotropin and thyroid cancer diagnosis: a systematic review and dose-response meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Prognosis and prognostic factors of patients with papillary carcinoma showing distant metastasis at surgery (M1 patients) in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Impact of moderate vs stringent TSH suppression on survival in advanced differentiated thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Does postoperative thyrotropin suppression therapy truly decrease recurrence in papillary thyroid carcinoma? A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Triiodothyronine levels in athyreotic individuals during levothyroxine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoring

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Quality of life in cured patients with differentiated thyroid carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Reversible diastolic dysfunction after long-term exogenous subclinical hyperthyroidism: a randomized, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Both exogenous subclinical hyperthyroidism and short-term overt hypothyroidism affect myocardial strain in patients with differentiated thyroid carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Prevalence of atrial fibrillation in patients taking TSH suppression therapy for management of thyroid cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Thyroid hormone use, hyperthyroidism and mortality in older women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Levothyroxine dose and risk of fractures in older adults: nested case-control study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Low Serum Thyrotropin Concentrations as a Risk Factor for Atrial Fibrillation in Older Persons

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Risk for fracture in women with low serum levels of thyroid-stimulating hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

The impact of age and gender on papillary thyroid cancer survival.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Quality of life in longterm exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

Osteoporosis and thyrotropin-suppressive therapy: reduced effectiveness of alendronate.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962205-3

7 January 2021

10.1016/S0140-6736(12)62205-3

Identifiers

DOI

1 reference

30 July 2017

1 reference